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ABSTRACT 
P   t‟s   s  s  of  on  (PDB)  s t   s  on  most fr qu nt m t  ol    on    s  s   ft r 
osteoporosis. Genetic factors play an important role in PDB, but to date PDB causing mutations 
were identified only in the Sequestosome 1 gene at the PDB3 locus. OPTN has been recently 
associated with PDB, however little is known about the effect of genetic variants in this gene in 
PDB pathophysiology. By sequencing OPTN in SQSTM1 non-carriers PDB patients we found 16 
SNPs in regulatory, coding and non-coding regions. One of those was found to be associated with 
PDB in our cohort - rs2234968. Our results show that rs2238968 effect may be explained by a 
change in OPTN splicing that give rise to a predicted truncated protein. We also performed 
functional studies on the variants located in OPTN promoter – rs3829923 and the rare variant -9906 
– to investigate putative regulators of OPTN. Our results show that OPTN expression seems to be 
regulated by SP1, RXR, E47, and the E2F family. In conclusion, our work suggests a potential 
pathophysiological role of SNPs in OPTN, giving a new perspective about the regulatory 
mechanisms of this gene. Ultimately we discovered a new variant associated with PDB in OPTN, 
reinforcing the relevance of this gene for the development of this bone disease. 
 
Keywords: P   t‟s   s  s  of  on   opt n ur n    n  r  ul t on  spl   n   rs  3 968 
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1. INTRODUCTION 
Opt n ur n w s f rst    nt f     y   ‟s  roup 1 using a yeast two-hybrid system and named FIP-2 - 
interacting protein of Adenovirus E3 14.7-kDa protein. Later, in 2002, mutations in this gene were 
found to be associated with primary open-angle glaucoma, a disease that causes irreversible 
bilateral blindness   n  t     n  w s r n m   “opt n ur n” (OPTN) 2. The human OPTN gene is 
located in the short arm of chromosome 10 (13099449-13138308) and spans about 39 Mbp of 
  nom   DNA  It  ont  ns t r   non o  n   xons  n t    ‟ untr nsl t   r   on (UTR)  n   3  xons 
that code for a 577 amino acid protein. Alt rn t v  spl   n   n t    ‟ UTR   n r t s  t l  st four 
different transcripts (NM_001008211.1, NM_001008212.1, NM_001008213.1, and 
NM_001008214.1), but all have the same open reading frame. Alternative splicing in the coding 
region give rise to three different protein isoforms with 571 (ENST00000378764), 126 
(ENST00000424614) and 107 (ENST00000486862) amino acids. Also, two partial transcripts were 
also described, but there is no indication of being protein coding. In addition   n        „n w f rst 
 xon‟ was described, upstream from the previously known exon 1, and was labelled as exon 1a 3. 
The OPTN protein consists of a NEMO-like domain, a leucine zipper motif, multiple coiled-coil 
motifs, an ubiquitin binding domain (UBD), a microtubule associated protein 1 light chain 3 (LC3)-
interacting motif, and a C-terminal zinc finger 
4
. OPTN is known to undergo posttranslational 
modifications, after being ubiquitinated it is processed through the ubiquitin-proteasome pathway 
5
. 
It is also phosphorylated at Ser177, which is adjacent to the LC3 interacting region (LIR) site 
6
. 
OPTN is a multifunctional protein involved in several biological functions such as NF-κB 
regulation, autophagy, membrane trafficking, exocytosis, vesicle transport, transcriptional 
activation, and reorganizing of actin and microtubules, since it interacts with several proteins, 
including Rab8, huntingtin, transcription factor IIIA, myosin VI, and TANK binding protein 1 
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(TBK1). OPTN biological role is not yet fully understood and appears to be complex and involve 
different mechanisms and pathways (reviewed in 
7
). Besides glaucoma, a number of diseases such 
as neurodegenerative diseases (l k  Alz   m r‟s   s  s   P rk nson‟s   s  s  8 and amyotrophic 
lateral sclerosis 
9
)  n  P   t‟s   s  s  of  on  (PDB) 3,10 have been associated with mutations in 
OPTN. PDB is the second most frequent metabolic bone disorder, after osteoporosis 
11
, affecting 
between 1% and 3% of individuals over the age of 55 years 
12,13
. This disease is characterized by 
focal abnormal bone remodelling, with increased bone resorption and accelerated, excessive, and 
disorganized new bone formation. The pathophysiology of PDB is currently an area of intensive 
investigation, and this disease seems to have both genetic and non-genetic causes. Fifteen to 40 
percent (15–40%) of affected patients have a first-degree relative with PDB, and numerous studies 
have described extended families with PDB exhibiting an autosomal dominant mode of inheritance 
14–16
. Linkage studies in these families have identified a number of susceptibility loci on 
chromosomes 6p21 (PDB1) 
17
, 18q21.1-22 (PDB2) 
18
, 5q35 (PDB3), 5q31 (PDB4) 
15
, 2q36 (PDB5) 
19
, 10p13 (PDB6) 
20
 and 18q23 (PDB7) 
19
. The regions identified are typically large and contain 
several genes that could be possible candidates based on their known functions. Moreover, a 
genome-wide scan in British families with PDB has shown a linkage to the 10p13 (PDB6) locus 
20,21
. Recently, reanalysis of data from this genome-wide scan confirmed a genetic association to 
the 10p13 locus 
10
, namely to the rs1561570 SNP located in OPTN gene, but no PDB causal 
mutation has been reported to date in this locus. Our group replicated the strong and statistically 
significant genetic association of rs1561570 (p-value = 5.65×10
−7
) with PDB in the French-
Canadian population 
3
, and also identified a functional SNP in UCMA/GRP, but with a marginal 
association with PDB, and a rare variant in OPTN promoter predicted to alter the putative binding 
of bone transcription factors 
3
. In this work, we have assessed the possible contribution of each 
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significant variant identified in the OPTN gene and have selected rs3829923 and rs2234968 to 
perform the association study and functional analysis in order to determine the involvement of 
these variants in the PDB pathophysiology. We also analysed the effect of a rare variant (RV -
9906) found in OPTN promoter and described in our previous work 
3
. 
 
2. MATERIAL AND METHODS 
2.1 Study participants and candidate gene sequencing 
This study was approved by the CHU de Québec-Université Laval Ethics Committee and all 
participants have signed a consent form before inclusion in the study. Phenotype assessment 
comprised a complete bone evaluation, including total serum alkaline phosphatase, a total body 
bone scan and skull and pelvis X-rays. We investigated patients with familial form of PDB (one 
patient per family), unrelated PDB patients and healthy controls, all from the French-Canadian 
population. Clinical characteristics of these cohorts were previously published 
22–24
. For each 
individual, peripheral blood was obtained as described in 
3
. All patients and healthy donors studied 
here were non-carrier of the P392L mutation within the SQSTM1 gene (PDB3 locus). RNA from 
total blood was collected as described in 
3
.  
 
2.2 OPTN genetic variation screening 
The strategies used throughout this study are briefly summarized in Fig. S1. To search for variants 
within the OPTN gene, the exons, their exon–intron boundaries   ‟  n  3‟-UTRs and the basal 
promoter were sequenced as previously described 
3
. Thirty samples from patients with PDB and 
five healthy controls from the French-Canadian population underwent Sanger sequencing, which 
we refer as the discovery group. For the association study, the SNPs rs3829923 and rs2234968 
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were selected to be genotyped in a group of 225 controls and 298 patients, based on their frequency 
in the discovery group and location in the gene. The allele frequencies were calculated as 
previously described 
3
. 
 
2.3 Bioinformatic analysis 
To identify the potential effect of the variants found in the coding regions we used the online 
translate tools Expasy (http://web.expasy.org/translate/), SIFT 
(http://siftdna.org/www/SIFT_dbSNP.html), Condel (http://bg.upf.edu/fannsdb/), Polyphen 
(http://genetics.bwh.harvard.edu/pph2/) and Mutation taster software 
(http://www.mutationtaster.org/). Potential changes in the splice sites were predicted using the 
Human Splicing Finder tool (http://www.umd.be/HSF/). To identify transcription factor binding 
sites (TFBSs) for the variants located in promoter regions we used TFsearch 
(http://diyhpl.us/~bryan/irc/protocol-online/protocol-cache/TFSEARCH.html) and Consite 
(http://consite.genereg.net/). To analyse the effect in the mRNA secondary structure we used RNA 
fold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). To search for SNPs in linkage disequilibrium 
(LD) we used the SNAP tool (https://www.broadinstitute.org/mpg/snap/).  
 
2.4 Preparation of human in vitro-differentiated mature osteoclasts  
Human mature osteoclasts were differentiated in vitro using mononuclear cells from blood of 
healthy controls and patients with PDB. Peripheral blood mononuclear cells (PBMCs) were 
obtained by density gradient centrifugation using Ficoll-Hypaque. The cells were resuspended 
(3x10
6
 cells/mL) in OPTI-MEM containing 10% FBS (Life technologies). The cell suspension was 
added to 6-well plates (9x10
6
 cells/well) and to Lab-Tek 8 well-slides (3-6x10
5
 cells/well). After 24 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 7 
h, the cells were washed thoroughly and lymphocyte-free adherent cells were incubated for three 
weeks with M-CSF (25 ng/ml, Life technologies) and RANKL (30 ng/ml, Fitzgerald). 
 
2.5 Quantitative real-time PCR 
In order to test if rs2234968 had an impact on OPTN gene expression, we performed qPCR as 
previously described 
3
. We used RNA from PBMCs of six patients and three healthy donors. A 
quantity of cDNA corresponding to 10 ng of total RNA was used in these analyses. The primers 
used are displayed in Table S1. For every assay, a negative control was performed in the absence of 
cDNA template. Fluorescence was measured at the end of each extension cycle and melting 
profiles of each reaction were performed to check for unspecific product amplification. Relative 
mRNA  xpr ss on w s   l ul t   us n  t   ΔΔCt m t o  25. Normalization was performed using 
the reference gene peptidylprolyl isomerase B (PPIB), since it was defined as a suitable reference 
  n  for mRNA qu nt ﬁ  t on  n p r p  r l w ol   loo  26. 
 
2.6 Western blot analyses 
Osteoclasts derived from PBMCs from patients and controls were washed once in PBS and lysed 
using Trizol. The protein concentrations were determined using the Bradford reagent (Bio-Rad). 
Proteins were separated by an 8 % SDS-polyacrylamide gels and transferred onto PVDF 
m m r n s (  f  t   nolo   s)  Aft r tr nsf r  t   m m r n s w r   lo k    n     % TBS/Tw  n 
    ont  n n    % nonf t  r    m lk  t room t mp r tur  for      T   m m r n s w r  t  n 
incubated overnight (ON)  t   °C w t   nt -OPTN (1:500, #100000 Cayman), or anti-αTu ul n 
( :      #     C ll S  n l n )  n     % TBS/Tw  n     follow    y  xt ns v  w s  n  us n     % 
TBS/Tween 20 and an incubation with HRP- onju  t   s  on  ry  nt  o y ( :       C ll 
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signal n )  n     % TBS/Tw  n     ur n    h, at room temperature. After extensive washing with 
    % TBS/Tw  n     sp   f   prot  ns w r    t  t   us n       m lum n s  n   k t (GE 
Healthcare). The densitometric analysis was performed using ImageJ software. 
 
2.7 In vitro functional analysis of OPTN promoter SNPs 
Four fragments of the OPTN promoter were amplified from human genomic DNA using four 
different primer sets to originate the constructs rs3829923 C/T and RV-9906 G/A. Briefly, a 1.2 kb 
fragment of the OPTN promoter ranging from -315 to +832 (related to the transcription start site) of 
the OPTN gene was amplified from human genomic DNA, using the primer set rs3829923 F1/R1 
(Table S1) – construct rs3829923 C. A point mutation, corresponding to the T allele of rs3829923 
(position -305), was generated by PCR using the forward primer rs3829923 F2 (Table S1) and the 
same reverse primer – construct rs3829923 T. A 1.1 kb DNA fragment of the OPTN promoter 
ranging from -241 to +832 was also amplified from human genomic DNA using the primer set RV 
-9906 F1/R1 (Table S1) – construct RV -9906 G. A point mutation corresponding to the A allele of 
RV −99 6 (pos t on -232), was generated by PCR using a different primer forward (RV -9906 F2; 
Table S1) and the same primer reverse – construct RV -9906 A. The amplified PCR products were 
cloned into pCRII TOPO (Invitrogen) and the fidelity of the sequence was confirmed by DNA 
sequencing. The DNA inserts were then cloned between the XhoI and KpnI sites of the pGL3-basic 
luciferase reporter gene vector (Promega) giving rise to construct F1 (corresponding to rs3829923 
C allele), construct F2 (corresponding to rs3829923 T allele), construct F3 (corresponding to RV -
9906 G allele), and construct F4 (corresponding to RV -9906 A allele). All constructs were 
confirmed by DNA sequencing. 
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2.8 Cell transfections and luciferase activity assay 
The human embryonic kidney HEK293 cell line was grown in Dulbecco's modified eagle medium 
(DMEM), supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine and 1% 
penicillin/streptomycin (P/S). The nonadherent THP1 cell line was cultured in RPMI 1640 medium 
supplemented with 10% FBS, 2 mM L-glutamine and 1% P/S. The cells were incubated at 37
o
C in 
a humidified atmosphere containing 5% CO2. The medium, FBS, antibiotics and glutamine were 
obtained from Invitrogen.  
HEK293 cells were  cultured on 24 well plates (5 x 10
4
 cells/well) and transiently transfected using 
XtremeGENE HP (Roche), with 250 ng of OPTN reporter gene rs3829923 C (F1), rs3829923 T 
(F2), RV -9906 G (F3), RV -9906 A (F4), or empty reporter vector (pGL3-basic). Co-transfections 
of an additional expression construct (50 ng/µl) carrying each transcription factor were performed 
using a similar approach.  
THP1 cells (5 x 10
4
 cells per sample) were transiently transfected with 500 ng of plasmids‟ DNA 
using electroporation (Lonza nucleofector technology)  n    or  n   w t  m nuf  tur r‟s 
instructions. Specifically, 100 µl Cell Line Nucleofector® Solution V were used. 
After 48 h the cells were lysed and luciferase activity was assayed using a Dual-luciferase Reporter 
Assay kit (Promega) in accordance with the manufacturer's instructions. All luciferase activities 
were normalized to the Renilla luciferase reporter pRL-Null Luc plasmid (Promega), which was 
unresponsive to the overexpression of the transcription factors used. All experiments were repeated 
at least three times. The SP1 expression plasmid and the RXR expression plasmid were a generous 
gift from Dr. Roland Schüle (Freiburg, Germany), the E47 expression plasmid was a generous gift 
from Dr. Xiao-Hong Sun (New York, USA), the E2F family expression plasmids were a generous 
gift from Dr. Lieve Verlinden (Leuven, Belgium), and the SAP1 expression plasmid was a 
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generous gift from Dr. Ralf Janknecht (Oklahoma, USA). 
 
2.9 Statistical analyses 
Statistical analyses were performed with GraphPad Prism 5 (GraphPad, La Jolla, CA). 
Comparisons between two groups were made using a two-t  l   Stu  nt‟s t-test. For comparisons 
between multiple groups, one-w y ANOVA follow    y Tuk y‟s post-hoc test was used. 
Differences were considered statistically significant when p<0.05. 
 
3. RESULTS 
3.1 Discovery study – Variants identification in OPTN 
In this analysis, we have detected 16 genetic variants and their position is shown in Fig. 1 and 
Table S2. Their respective frequency in the discovery group and in silico predicted functions are 
shown in Table S3. We found two variants with predicted effects on protein sequence, 16 variants 
predicted to cause loss and/or gain of TFBSs, seven variants predicted to have an effect on splicing, 
and eight variants predicted to cause loss and/or gain of miRNA binding sites (Table S3). 
 
3.2 Association study – Selection of the most relevant variants found in the discovery study 
From all these variants, we selected rs3829923 and rs2234968 for genetic association with PDB in 
our French-Canadian cohort. The two variants were selected due to the high frequency in the 
discovery group (rs3829923 – found in 13 of the 30 patients and in none of the healthy controls; 
rs2234968 – found in 15 patients and in three of five controls), due to the minor allele frequency in 
the European population (25% for rs3829923 and 18% for rs2234968), and due to their localization 
in the gene (rs3829923 is located in OPTN promoter and can affect its expression, and rs2234968 is 
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located in OPTN coding region and can affect either protein-protein interactions, OPTN role or 
localization in the cell, or its mRNA secondary structure). The genotypes of these variants were in 
Hardy-Weinberg equilibrium in controls (data not shown). The genetic association study 
demonstrated that only rs2234968 was associated with PDB (MAF in patients = 33%, MAF in 
controls = 25%, uncorrected p-value = 6 x 10
−3
, OR = 0.6674; CI 95% = [0.50 ; 0.89]). This 
association was further replicated in an Italian population composed by 364 controls and 475 PDB 
patients (MAF in patients = 39%; MAF in controls =32%, uncorrected p-value = 4 x 10
−3
). The 
association study also showed that rs3829923 was not associated with PDB (MAF in patients = 
34%, MAF in controls = 33%, uncorrected p-value = 1, OR = 1.0006; CI 95% = [0.76 ; 1.32]). 
  
3.3 Effect of rs2234968 in OPTN splicing and protein sequence 
Several possible functional effects of rs2234968 were analysed: 1) OPTN mRNA secondary 
structure according to RNA fold program revealed an absence of a predicted effect in mRNA 
structure (Fig. S2A); 2) OPTN expression levels by qPCR using patients and healthy donors 
samples with all genotypes, showed an absence of correlation between genotype and OPTN 
expression levels (Fig. S2B); and 3) OPTN splicing pattern, according to Human Splicing Finder 
tool, indicated a prediction of a new branch point (73% of probability) and consequently a possible 
exon 5 skipping, which would change the protein sequence (Fig. S2C). However, by doing a PCR 
using primers flanking exon 5 and cDNA from patients as template, we showed that rs2234968 did 
not induce exon 5 skipping (Fig. S2D). We then searched for SNPs in linkage disequilibrium (LD) 
with rs2234968, which may have a functional effect and explain the association of PDB with 
rs2234968. We found four SNPs [rs76647957 (r
2
 = 0.831; DPrime = 0.912), rs12415802 (r
2
 = 
0.831; DPrime = 1), rs10906303 (r
2
 = 0.958; DPrime = 1) and rs79529484 (r
2
 = 0.801; DPrime = 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 12 
0.954)] in LD with rs2234968 that are located in OPTN introns 2, 3, 5 and 6, respectively (Fig. 
2A). Using Human Splicing Finder tool, we determined that rs10906303 and rs79529484 were the 
most likely to have a functional effect on splicing, since the results show that rs10906303 has a 
high probability to create a new donor splice site and a new acceptor splice site, and rs79529484 
also has a probability to create a new acceptor splice site, while the other SNPs analysed did not 
have a predicted effect on splicing (Fig. 2B). These effects were tested by PCR using cDNA 
samples from patients with all genotypes and specific primers (Fig. 2C). Results showed that both 
rs10906303 and rs79529484 had the potential to alter the splicing sites, causing retention of introns 
5 and 6 respectively (Fig. 2C), which would change the amino acid sequence and lead to a 
predicted premature stop codon (Fig. 2D). By using an antibody against the OPTN C terminus in a 
western blot analysis, we detected lower OPTN protein levels in the presence of rs2234968 A allele 
(Fig. 2E), but not an additional band corresponding to a truncated protein, suggesting that the A 
allele might be producing a truncated protein lacking the region recognized by the antibody used (C 
terminus), as predicted by our in silico analysis.  
 
3.4 In silico prediction of transcription factor binding sites in rs3829923 and RV -9906 
located in OPTN promoter 
In order to explore the functional effect of the variants located in OPTN promoter, we searched for 
TFBSs that could be potentially interrupted by these variants, using the online tools Consite and 
TFSearch. Rs3829923 causes a change from a C allele to a T allele (Fig. 3A) and the bioinformatic 
software predicted the putative binding sites for SAP1, NRF2, E74A and E2F family in the region 
of the rs3829923 carrying the C allele, which are lost in the presence of the T allele. On the other 
hand, in the presence of the T allele the software predicted a putative binding site for E47 
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transcription factor (Fig. 3B). We also assessed the putative effect of OPTN RV -9906 G/A (Fig. 
3C), a polymorphism previously reported 
3
, in OPTN promoter activity. The in silico analysis 
revealed that SP1, PAX4 and RXR binding sites are potentially interrupted by -9906 A allele, 
possibly resulting in loss of their binding efficiencies as compared with the -9906 G allele. In 
addition, putative binding sites for HNF4 and PPAR were identified only in the presence of the A 
allele (Fig. 3D). 
 
3.5 Functional analysis of rs3829923 in OPTN promoter 
To analyze the functionality of the two different alleles of rs3829923, we transfected HEK293 cells 
and performed luciferase assays with the two constructs, F1 and F2, carrying respectively the C or 
the T alleles. The results showed an increase in OPTN promoter activity in construct F2 when 
compared to construct F1, both in HEK293 (Fig. 4A) and in THP1 (Fig. 4B). The cells were then 
transfected with the F1 construct or the F2 construct together with the transcription factors (TFs) 
predicted to bind to this region in the in silico analysis. The co-transfection of F1 with E47 and 
E2F1 showed no effect of these TFs when a C allele is present (Fig. 5A,B). In contrast, co-
transfection of F2 with either E47 or E2F1 showed a significant increase in OPTN promoter 
activity, suggesting a potentiating effect of these TFs in gene transcription when the T allele is 
present (Fig. 5D). No significant effects were observed with SAP1 (Fig. 5E) nor with E2F2, E2F4 
and E2F5 (Fig. 5D), while a positive effect on gene transcription was observed for both constructs 
with E2F3 (p-value < 0.0001) thus indicating that it was independent of the C/T variant present 
(Fig. 5A,D). In order to assess if this positive effect of rs3829923 T allele in OPTN promoter 
activity was related to an increase in OPTN expression in patients‟ cells, we performed a western 
blot analysis using osteoclasts derived from PDB patients PBMCs that were differentiated in vitro 
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as described in the material and methods section. However, the in vitro effect seen in the 
transfection assay was not reproduce   n p t  nts‟ ost o l sts  s n   t   pr s n   of rs38 99 3 T 
allele did not affect the OPTN protein levels (Fig. 6). The overexpression of all transcription 
factors was assessed by qPCR (Fig. 5C,F). 
 
3.6 Functional analysis of the rare variant RV -9906 in OPTN promoter 
To analyse the functionality of the two different alleles of RV-9906, we transfected HEK293 cells 
and performed luciferase assays with the two constructs, F3 and F4, carrying respectively the G or 
the A alleles. The transient transfections of HEK293 cells with constructs F3 showed a significantly 
lower activity than with F4 (Fig. 7A), indicating that the presence of the A allele (F4 construct) 
increases the transcriptional activity of the OPTN gene. By transient co-transfections we showed 
that SP1 reduces luciferase expression only in the presence of the F3 construct (Fig. 7B,E), 
indicating that the effect obtained is specific for the G allele. After co-transfections of HEK293 
cells with either F3 and F4 constructs and with RXR, we observed a decrease in OPTN promoter 
activity with both constructions when the cells were treated with the RXR ligand retinoic acid (RA) 
(Fig. 7C,F), which indicates that, in fact, RXR has a binding site in OPTN promoter but that it is 
independent of the G/A variant of RV -9906 present. The overexpression of all transcription factors 
was assessed by qPCR (Fig. 7D,G). The effect of RV -9906 in OPTN protein levels was not 
assessed in the PBMCs from PDB patients because this rare variant was present in only one PDB 
patient who was not available for follow up.  
 
4. DISCUSSION 
In the present study, we investigated the functional role of three genetic variants within OPTN 
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locus found in the French-Canadian cohort. We detected 16 variants already reported in the NCBI 
database and we focussed our analysis in three variants: rs3829923 and rs2234968, discovered in 
our present work and a rare variant found in OPTN promoter – RV-9906 – discovered in a previous 
work from our group 
3
.  
Regarding rs2234968 we found that it was associated with PDB in our population (uncorrected p-
value = 6 x 10
−3
) as well as in the Italian population (uncorrected p-value = 4 x 10
−3
), which 
reinforces the importance and significance of this recently associated variant in PDB pathology. 
However, our results showed that it has no functional effect on PDB pathogenesis per se. Instead 
we found two SNPs (rs10906303 and rs79529484) in LD with rs2234968 that could explain the 
association of this variant to PDB. Then, we analysed the effect of rs10906303 and rs79529484 in 
the splicing pattern of OPTN gene and showed that these SNPs caused the retention of intron 5 and 
intron 6 respectively, producing new OPTN transcripts, both leading to premature stop codons. We 
hypothesize that these new transcripts encode smaller truncated proteins predicted to lose OPTN 
protein domains, namely the NEMO, UBD and LIR domains which, similarly to the deleterious 
effect of SQSMT1 mutations, that impair its main functional domain - UBA
 
- 
22
, should impair 
OPTN function and thus contribute to the PDB phenotype. Accordingly, an OPTN transcript with a 
retained intron 5 was already described in patients with other diseases like juvenile open-angle 
glaucoma 
27
, thus confirming the presence of this abnormal transcript and indicating that it can alter 
OPTN function or the normal regulation of its protein expression 
28
. Also, Obaid et al 2015 had 
already described a negative role for OPTN in osteoclastogenesis 
29
, which is in accordance with 
our results. Nevertheless, further studies will be required to clarify the effect of these transcripts in 
PDB patients. By quantifying their expression and comparing it with the expression of the normal 
tr ns r pts   n   n lys n   f OPTN fun t on  s  mp  r   w  n only t   mut nt “s ort” tr ns r pt  s 
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expressed, should be highly relevant to further understand its effect in associated pathologies such 
as PDB. In addition, analysis of the resulting autophagy process or of the expression of osteoclast 
related genes might also contribute to clarify the effect of these variants in PDB pathophysiology.  
The fact that this SNP was also found in some healthy controls also indicate that other factors such 
as, for example, the presence of paramyxovirus, may be required for the development of this 
disease, and this should also be further investigated. This co-effect of paramyxovirus and genetic 
mutations was already described by Kurihara‟s  roup  w o found that p62 knockin mice bred with 
measles virus nucleocapsid gene (MVNP) mice develop greater numbers of pagetic-like 
osteoclasts and more dramatic bone lesions than do MVNP mice or p62 knockin mice alone. 
30
 
In this work we also analysed the effect of two variants found in OPTN promoter: rs3829923 – that 
was present in 13 patients and not in any of the controls tested - but that after the association study 
was found not to be associated with PDB (uncorrected p-value = 1); and RV -9906 - a rare variant 
found only in one PDB patient
3
. Although not being associated with PDB, since these variants were 
located in OPTN promoter we hypothesized that they could alter OPTN expression by affecting 
TFs binding and in that case its functional study would potentially unravel new OPTN regulators. 
Rs3829923 was shown to increase OPTN promoter basal activity, and following co-transfections 
we concluded that E47 and E2F1 have an inductive effect only in the presence of the T allele. E47 
is a member of bHLH family and it was described as important for osteoclast maturation and 
survival
 31
. Therefore the gain of an E47 binding site could contribute to explain the onset of a PDB 
phenotype since it might be related to an increase in osteoclast survival, giving rise to PDB 
features. E2F1 has been associated with osteoblast differentiation and mineralization 
32
, and cell 
proliferation
33
, and this may also contribute to explain the deregulation in the number of osteoblasts 
(and also osteoclasts) observed in this disease in the presence of the T allele. However, the 
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observed in vitro effect due to the presence of the rs3829923 T allele, was not reflected as an 
increase in OPTN protein levels in osteoclasts of patients carrying the rs3829923 T allele, which 
may explain why this variant was not significant in our association study.  
A functional analysis of RV-9906 showed that, following co-transfections in HEK293 cells with 
the OPTN promoter carrying either the G or the A allele, together with SP1 and RXR TFs, we could 
conclude that RV-9906 A allele was in fact responsible for a loss of SP1 inhibitory effect whereas it 
did not alter the RXR effect. Polymorphisms occurring in SP1 binding sites were previously 
associated with changes in bone mineral density and osteoporosis 
34
 and SP1 has been described as 
an important regulator for osteoclast related genes, like RANKL 
35
 and BMP2 
36
. Our study 
suggests that SP1 is likely to be an important regulator of OPTN since a single alteration in its 
DNA binding site changed its activity, probably by preventing SP1 binding to the OPTN promoter. 
Unfortunaltely, the protein levels measured in the osteoclasts of the patient carrying RV-9906 were 
not assessed since the patient did not return for his follow up consultation.  
To complement this analysis of the variants in OPTN promoter, an electrophoretic mobility shift 
assay (EMSA) should be performed in order to confirm if, in fact, SP1, E47 and E2F1 are binding 
to the cloned promoters. A chromatin immunoprecipitation assay (CHIP) could also be performed 
aiming at providing additional data to confirm the presence of these bona fide TFBSs in vivo. In 
addition, to clarify the role in PDB of the promoter variants identified in this study and its effect in 
osteoclastogenesis, it would be of interest to do in vitro site directed mutagenesis and develop 
osteoclast precursor isogenic cell lines with and without the mutations, aiming at replicating the 
expression of the two identified transcript variants and analyzing its effect in the number and 
activity of resulting osteoclasts. These functional analysis will be a subject of future research. 
Nevertheless, the results obtained in this work already showed that SP1, E47 and E2F1 could be 
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new potential regulators of OPTN promoter activity, and therefore also new potential therapeutic 
targets for OPTN related diseases. Furthermore, since these are all bone associated transcription 
factors, results also suggest a potential role of OPTN in bone metabolism. 
 
5. CONCLUSION 
In conclusion, genetic variants of OPTN gene seem to be important in PDB patients. We identified 
two SNPs in linkage disequilibrium with rs2234968, a new variant associated with PDB, that are 
responsible for a change in splicing and possibly for creating a new truncated protein, probably 
non-functional, providing some insights about the role of this variant in the PDB phenotype of 
these patients. These data, together with the fact that OPTN seems to be regulated by bone related 
transcription factors such as E2F1, SP1 and E47, reinforce the relevance of this gene in the PDB 
pathophysiology. 
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TITLES AND LEGENDS TO FIGURES 
Fig. 1 – Localization of the genetic variants found in OPTN 
Schematic representation of the OPTN gene. The arrows indicate the transcription start sites and 
orientation in the chromosome. The light grey boxes represent non-coding exons, and the dark grey 
represent coding exons. The numbers below the boxes represent the exons length in base pairs. The 
bars represent the SNPs located in the introns and the arrowheads represent the SNPs located in the 
exons. 
 
Fig. 2 – SNPs in Linkage Disequilibrium with rs2234968 
(A) Localization of the SNPs in linkage disequilibrium with rs2234968. The numbers above the 
boxes (exons) represent the exons length in base pairs. The numbers below the lines (introns) 
represent the introns length in base pairs; (B) In silico prediction of the effects of the SNPs in 
linkage disequilibrium with rs2234968, in OPTN splicing; (C) Localization of the primers (F1, R1, 
F2, R2) used to amplify by PCR the different transcripts and electrophoresis results showing that 
with the presence of one mutated allele there is a change in OPTN splicing pattern. AA, AG, GG, 
TT, and TG represent different genotypes from patients samples and B represents the PCR negative 
control; (D) OPTN protein sequence showing a premature stop codon - predicted by the position of 
the stop codon from the cDNA sequence from patients (represented by an *) - due to the effect of 
rs10906303 (grey box) and rs79529484 (black dashed box) in splicing. The bold and grey amino 
acids represent the new protein derived from the retention of the intron. (E) Analysis of OPTN 
protein expression in PBMCs-derived osteoclasts from non-mutated controls (GG) (n=3), non-
mutated patients (GG) (n=2) and one patient heterozygeous (GA) for rs2234968, which was also 
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heterozygous for the two intronic SNPs in LD. The results are relative to three independent western 
blot analyses for each sample. 
 
Fig. 3 – In silico prediction of the effect of rs3829923 and RV -9906 
(A) rs3829923 localization in OPTN gene (Chr10:13099144) showing that this variant is present in 
OPTN promoter and is responsible for a change from a C to a T. (B) Bioinformatics prediction 
showing putative binding sites for NRF2, SAP1, E74A and E2F in the presence of the C allele, and 
a E47 putative binding site in the presence of T allele. (C) RV -9906 localization in OPTN gene 
(Chr10:13099216) showing that this variant is present in OPTN promoter and it is responsible for a 
change from a G to an A. (D) Bioinformatics prediction shows the presence of PAX4, SP1, and 
RXR putative binding sites in the presence of the RV -9906 G allele and the presence of HNF4 and 
PPAR putative binding sites in the presence of RV -9906 A allele. TSS1 represents the first 
transcription start site (Chr10:13099449) and TSS2 represents the second transcription start site 
(Chr10:13099959). 
 
Fig. 4 - rs3829923 effect in OPTN basal promoter activity 
Transient transfections of (A) HEK293  and (B) THP1 cells showing that the F2 construct 
(rs3829923 T allele) had a significantly higher activity than the construct F1 (rs3829923 C allele). 
Data are the mean ± SD of at least three independent experiments. Significance was determined by 
one-way Anova. Asterisk *** represents a p-value < 0.001. **** indicates that all the constructs 
used are significantly different from the promoter less vector pGL3-basic (p-value < 0.0001). 
 
Fig. 5 - rs3829923 effect in transcription factor binding  
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(A) Co-transfection assays showing that E2F3 have an activating effect in F1, while (B) co-
transfection with SAP1 revealed that this transcription factor does not have an effect in the 
presence of rs3829923 C allele. (C) qPCR results show that all of the transcription factors were 
overexpressed after co-transfection with F1 construct. Data are the mean ± SD of at least three 
independent experiments. Significance was determined by one-way Anova. Asterisk ** represents 
a p-value < 0.01. (D)  Co-transfection assays showing that F2 construct (carrying the T allele) had a 
significant increase of luciferase expression, in the presence of E47 and E2F1 not observed with F1 
construct (carrying the C allele), indicating that the effect of E2F1 and E47 is specific of the T 
allele. E2F2, E2F4 and E2F5 did not have a significant effect on both constructs. (E) Co-
transfection with SAP1 revealed that this transcription factor does not have an effect in the 
presence of rs3829923 T allele.  Data are mean ± SD of at least three independent experiments. 
Significance was determined by one-way Anova. Asterisk * indicates a p-value = 0.01. **** 
indicates that all the constructs used are significantly different from the promoter less vector pGL3-
basic (p-value < 0.0001). (F) qPCR results show that all of the transcription factor swere 
overexpressed after co-transfection with F2 construct. Data are the mean ± SD of at least three 
independent experiments. Significance was determined by one-way Anova. Asterisk ** represents 
a p-value < 0.01. 
 
Fig. 6 - rs3829923 effect in OPTN protein expression 
Analysis of OPTN protein expression in PBMCs-derived osteoclasts from non-mutated patients 
(CC) (n=2) and one patient homozygous for rs3829923 (TT). Data are mean ± SD of at least three 
independent experiments. Significance was determined by a two-t  l   Stu  nt‟s t-test 
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Fig. 7 - RV -9906 effect in OPTN basal promoter activity 
(A) Transient transfections of HEK293 cells showing that the F4 construct (carrying RV -9906 A 
allele) had a significantly higher activity than the F3 construct (carrying the RV -9906 G allele). 
(B) Transient co-transfections of HEK293 cells showing that F3 construct (containing the G allele) 
had a significant inhibition of luciferase expression, in the presence of SP1 and (C) RXR. (D) 
qPCR results show that all of the transcription factors were overexpressed after co-transfection 
with F3 construct. Data are the mean ± SD of at least three independent experiments. Significance 
was determined by one-way Anova. Asterisk ** represents a p-value < 0.01. (E) Transient co-
transfections of HEK293 cells showing that SP1 does not have any ihnibitory effect in the presence 
of the F4 construct  (containing the A allele). (F) Co-transfections with RXR revealed that this 
transcription factor also had an inhibitory effect in the presence of F4. Data are mean ± SD of at 
least three independent experiments. Significance was determined by one-way Anova. Asterisk * 
indicates a p-value < 0.05, *** represents a p-value < 0.001, **** indicates that all the construct 
used are significantly different from the promoter less vector pGL3-basic (p-value < 0.0001). (G) 
qPCR results show that all of the transcription factors were overexpressed after co-transfection 
with F4 construct. Data are the mean ± SD of at least three independent experiments. Significance 
was determined by one-way Anova. Asterisk ** represents a p-value < 0.01.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 26 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 27 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 28 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 29 
Figure 4 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 30 
Figure 5 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 31 
Figure 6 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 32 
Figure 7 
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Highlights 
 
- rs2234968 is a new variant  sso   t   w t  P   t‟s   s  s  of  on   
- rs10906303 and rs79529484 are in linkage disequilibrium with rs2234968. 
- rs10906303 and rs79529484 change OPTN splicing and might produce a truncated protein. 
- OPTN promoter is regulated by bone related transcription factors. 
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